Home > Formulary : Adult > Recent Decisions > 2023 >
Decisions 27th June 2023
New Drug Requests
Approved
Methoxyflurane (inhaled) (Penthrox®) (TLS Red)
-
For pain relief for brachytherapy applicator removal and pre-radiotherapy rectal spacer insertion
Methoxyflurane (inhaled) (Penthrox®) (TLS Red)
-
For pain relief for painful dressings changes for patients with painful leg ulcers who require rapid onset analgesia for a short duration
Itulazax (Standardised allergen extract of pollen from white birch [Betula verrucosa]) (TLS Red)
-
For treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group for use by the specialist allergy team.
Beclometasone / Formoterol / Glycopyrronium (Trimbow® pMDI 172/5/9) (TLS Blue)
-
For maintenance treatment of asthma
Shared Care Protocols
-
Nil
Traffic Light Status Change Requests
-
Nil
Other Formulary Decisions
-
The BNSSG SCP Review Process was approved
Further Work
Biologics and Apremilast for psoriasis update- further work needed
-
The new drug request application for biologics (adalimumab, infliximab, etanercept, tildrakizumab, certolizumab, risankizumab, guselkumab, brodalumab, ixekizumab, secukinumab, bimekizumab, ustekinumab) and apremilast for severe psoriasis at localised, high impact sites was discussed by the Joint Formulary Group. Further work is needed before any changes can be made to the current formulary position including financial considerations and update to the psoriasis biologics pathway. The current formulary position remains in place until this work is complete.